Sciety is currently capitalizing a Phase II pharmaceutical company and a DNA sequencing tech company––both via private placements. The companies operate in high growth markets and raise new capital to achieve product development goals that will lead to acquisition within the next twenty-four months. Drug candidate with a
Lipid imbalances does not only cause common diseases such as diabetes and cardiovascular diseases but also various rare diseases. The pharma company Lipigon is specialised in diseases caused by lipid imbalances, with an initial focus on rare diseases that lack adequate treatments. New candidate for treatment of severe disease
CARTANA raised almost 10 million SEK in a share issue that was fully subscribed at the end of September. The company has developed reagents for analysing tissue samples in drug development processes and is based at Karolinska in Stockholm. The new capital will be used for the sale of CARTANA’s
Cartana is based at Karolinska Institute in Stockholm and has developed a new technology for researchers to analyse tissue samples in drug development processes. The company is ready to launch at the market for brain research and will launch on the market for cancer research within a few years.
Last updated: 2023-09-12 If you’re used to buying shares on the stock market, it doesn’t have to be a big leap to invest in unlisted companies as well. At Sciety, we frequently receive questions from people who are considering making their first investment in an unlisted company. Practically speaking, how
Neurological disorders have been pinpointed by WHO as one of the greatest threats to public health. As an example, nearly 10 million people develop dementia each year and the number of people living with dementia is expected to triple from 50 million to 152 million by 2050. Today, the annual